Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine after neoadjuvant chemotherapy in breast cancer
NCT03011060Phase 3Unknown
- Sponsor
- The First Hospital of Jilin University
- Start
- Dec 2016
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer (3 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Disease-free survival at 5 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03011060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011060.